Sign in Subscribe
Cancer

Molecular Mechanisms of MHC-II Expression Regulation

Strategic Insights

— 1 min read

Research by a team of scientists at the National Cancer Institute (NCI) has uncovered new molecular mechanisms for regulating MHC class II (MHC-II) expression in antigen-presenting cells (APCs). The study reveals that the E3 ubiquitin ligase March-I controls the turnover of surface pMHC-II on APCs, while the protein CD83 suppresses endogenous March-I-dependent MHC-II ubiquitination, endocytosis, and degradation.

Key Takeaways:

  • The E3 ubiquitin ligase March-I plays a crucial role in controlling the turnover of surface pMHC-II on APCs, with approximately 500 March-I molecules/cell expressed in resting spleen DCs and 125 March-I molecules/cell in resting spleen B cells.
  • CD83 suppresses endogenous March-I-dependent MHC-II ubiquitination, endocytosis, and degradation in mouse spleen DCs, highlighting its regulatory function in MHC-II expression.
  • The study demonstrates that March-I protein has a short half-life in DCs, with rapid termination of March-I mRNA, March-I protein, and MHC-II ubiquitination upon activation of both DCs and B cells.
  • Analysis of quantitative data revealed that resting spleen DCs and B cells express March-I at similar levels, with approximately 500 and 125 March-I molecules/cell, respectively.
  • The research further highlights the unique regulation of MHC-II expression in APCs by March-I and CD83, with implications for understanding immune responses and developing novel therapeutic strategies.
  • The study's findings have significant implications for understanding the molecular mechanisms regulating MHC-II expression and its role in immune responses.

Statistics:

  • 500 March-I molecules/cell expressed in resting spleen DCs.
  • 125 March-I molecules/cell expressed in resting spleen B cells.
  • March-I protein has a short half-life in DCs.
  • Ratios of March-I mRNA, March-I protein, and MHC-II ubiquitination are rapidly terminated upon activation of both DCs and B cells.

Sources:

  • NewsRx. New Endocytosis Study Findings Have Been Reported by Researchers at National Cancer Institute (NCI) (Cd83 Suppresses Endogenous March-i-dependent Mhc Class Ii Ubiquitination, Endocytosis, and Degradation). Health & Medicine Week. July 4, 2025; p 2529.
  • Proceedings of the National Academy of Sciences, 2025;122(21).
  • National Academy of Sciences - www.nasonline.org/.
  • Proceedings of the National Academy of Sciences - www.nasonline.org/publications/pnas/.
  • National Cancer Institute (NCI) - Experimental Immunology Branch, Bethesda, MD 20892, United States.

Read more